Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Healthcare company Surgery Partners (NASDAQ:SGRY) met Wall Streets revenue expectations in Q3 CY2025, with sales up 6.6% year on year to $821.5 million. On the other hand, the company’s full-year revenue guidance of $3.29 billion at the midpoint came in 2% below analysts’ estimates. Its non-GAAP profit of $0.13 per share was 19% below analysts’ consensus estimates.
Surgery Partners (SGRY) Q3 2025 results miss analyst estimates for both revenue and earnings, causing a negative market reaction in pre-market trading.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how outpatient & specialty care stocks fared in Q2, starting with Surgery Partners (NASDAQ:SGRY).
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains.
This unpredictability can shake out even the most experienced investors.
UnitedHealth Group (NYSE: UNH), a titan in the U.S. healthcare industry, is grappling with a formidable array of financial and operational challenges that are poised to exert immediate and substantial downward pressure on its Q3 2025 Earnings Per Share (EPS) estimates. A confluence of escalating high-acuity care costs, unfavorable
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names.
But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry’s return was flat while the S&P 500 climbed by 10.5%.
A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested that with inflation risks moderating and unemployment remaining low, the Federal Reserve might consider a shift in its monetary policy stance, including potential interest rate cuts. This outlook eased market concerns about prolonged high interest rates and their impact on economic growth. The prospect of lower borrowing costs bolstered investor confidence, particularly in sectors that have lagged, leading to a broad rally across the market.
A number of stocks fell in the afternoon session after markets continued to decline, as investors grew cautious ahead of a key speech by Federal Reserve Chair Jerome Powell. The move came as U.S. equity markets recorded a fifth consecutive day of losses for major indexes like the S&P 500, with technology stocks experiencing the largest declines. Investors have grown wary that the sharp rally in the tech sector since April may have advanced too far. The market-wide caution is largely driven by the upcoming Jackson Hole symposium, a meeting of central bankers, where traders are anxiously awaiting Fed Chair Powell's speech on Friday for guidance on the future path of interest rates.
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth-oriented sectors like healthcare, as they reduce the cost of borrowing for research and innovation and increase the present value of future earnings.
Healthcare company Surgery Partners (NASDAQ:SGRY) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 8.4% year on year to $826.2 million. The company expects the full year’s revenue to be around $3.38 billion, close to analysts’ estimates. Its non-GAAP profit of $0.17 per share was 25.8% above analysts’ consensus estimates.
Healthcare company Surgery Partners (NASDAQ:SGRY) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 8.4% year on year to $826.2 million. The company expects the full year’s revenue to be around $3.38 billion, close to analysts’ estimates. Its non-GAAP profit of $0.17 per share was 25.8% above analysts’ consensus estimates.
SURGERY PARTNERS INC (SGRY) reported mixed Q2 2025 results, missing revenue estimates but beating EPS expectations. Shares rose 0.56% pre-market as investors weighed the earnings beat against the revenue shortfall. Full-year guidance was reaffirmed.
